Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.

ABSTRACT: In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3-<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab https://bit.ly/3pOTw93.

SUBMITTER: Pavord ID 

PROVIDER: S-EPMC9062111 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature